Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Bought by Casdin Capital LLC

Casdin Capital LLC grew its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 26.9% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,555,000 shares of the company’s stock after acquiring an additional 330,000 shares during the quarter. Structure Therapeutics accounts for approximately 3.6% of Casdin Capital LLC’s investment portfolio, making the stock its 8th biggest position. Casdin Capital LLC owned about 2.70% of Structure Therapeutics worth $43,540,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of GPCR. State of Wyoming bought a new position in Structure Therapeutics during the second quarter worth about $28,000. EverSource Wealth Advisors LLC boosted its holdings in Structure Therapeutics by 530.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after purchasing an additional 901 shares during the period. PNC Financial Services Group Inc. grew its position in shares of Structure Therapeutics by 29.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock worth $92,000 after purchasing an additional 994 shares in the last quarter. ANTIPODES PARTNERS Ltd grew its position in shares of Structure Therapeutics by 39.1% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock worth $114,000 after purchasing an additional 1,146 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Structure Therapeutics during the second quarter worth approximately $129,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on GPCR shares. JPMorgan Chase & Co. lifted their price target on shares of Structure Therapeutics from $65.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, January 22nd. Guggenheim raised their price objective on Structure Therapeutics from $90.00 to $140.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. The Goldman Sachs Group raised Structure Therapeutics to a “strong-buy” rating in a report on Tuesday, January 20th. Citigroup reiterated an “outperform” rating on shares of Structure Therapeutics in a research report on Friday, December 12th. Finally, BMO Capital Markets reissued an “outperform” rating on shares of Structure Therapeutics in a report on Tuesday, January 6th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $107.90.

Structure Therapeutics Stock Down 1.5%

Shares of GPCR stock opened at $53.75 on Friday. The business has a fifty day simple moving average of $73.46 and a 200 day simple moving average of $49.50. The company has a market cap of $3.81 billion, a P/E ratio of -68.04 and a beta of -1.80. Structure Therapeutics Inc. Sponsored ADR has a twelve month low of $13.22 and a twelve month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14). As a group, equities research analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.